The rare co-occurrence of cholangiocarcinoma and chronic eosinophilic leukemia
Open Access
- 23 April 2025
- journal article
- Published by VM Media Group sp. z o.o in Oncology in Clinical Practice
- Vol. 22
Abstract
Introduction. Cholangiocarcinoma (CCA) is a rare and highly aggressive malignancy of the bile ducts with a poor prognosis and a 5-year survival rate of approximately 5%. Chronic eosinophilic leukemia (CEL), characterized by clonal eosinophil proliferation, is a rare hematologic malignancy often progressing to acute leukemia. The simultaneous occurrence of these two malignancies is exceedingly rare, according to available research, this is the first case reported in the literature. Case report. This is the case of a 44-year-old female presenting with fatigue, diagnosed with metastatic CCA following imaging and biopsy. During chemotherapy with gemcitabine and cisplatin, the patient developed unexplained leukocytosis and eosinophilia, leading to a subsequent diagnosis of CEL. Despite aggressive treatment, the patient experienced complications, including cholangitis and renal failure, and succumbed to her illness four months post-diagnosis. Conclusions. This case highlights the rare co-occurrence of CCA and CEL, emphasizing the importance of vigilant monitoring for secondary hematologic malignancies in oncology patients. Early recognition and treatment of concurrent disorders can improve clinical outcomes and inform future research on such rare malignancy combinations. Keywords: cholangiocarcinoma chronic eosinophilic leukemia chemotherapy concurrent malignanciesKeywords
This publication has 20 references indexed in Scilit:
- Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemiaLeukemia, 2024
- Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinomaScientific Reports, 2022
- WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo ClinicAmerican Journal of Hematology, 2020
- Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published dataCritical Reviews in Oncology/Hematology, 2019
- Biological Role and Therapeutic Potential of IDH Mutations in CancerCancer Cell, 2018
- Treatment and Prognosis for Patients With Intrahepatic CholangiocarcinomaJAMA Surgery, 2014
- IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic TargetsFuture Oncology, 2013
- Chronic eosinophilic leukemia‐not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformationAmerican Journal of Hematology, 2012
- Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment UpdateMayo Clinic Proceedings, 2010
- The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementBlood, 2004